Annexon ANNX 深 沪
已收盘 10-16 16:00:00 美东时间
3.41
-0.190
-5.28%
华盛通- 最 高3.61
- 今 开3.60
- 成交量 524.00万股
- 最 低 3.355
- 昨 收 3.60
- 总市值 6.46亿
- 52周最高 7.18
- 市盈率 静 --
- 换手率 2.76%
- 52周最低 2.54
- 委 比 92.72%
- 总股本 1.90亿
- 历史最高 38.01
- 量 比 1.82
- 振 幅 7.08%
- 历史最低 1.285
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Annexon, Inc. announced two oral presentations on vonaprument at The Retina Society's 59th Annual Meeting, highlighting Phase 2 vision protection findings and the design of the Phase 3 ARCHER II trial for geographic atrophy (GA). The presentations emphasize the replication of key baseline characteristics between Phase 2 and Phase 3 patient populations, aiming to confirm vonaprument's potential to protect vision across a broad GA population. Vonap...
09-24 12:00
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. granted stock options to two new non-executive employees under its 2022 Employment Inducement Award Plan. The options, totaling 275,500 shares with a $3.92 exercise price, vest over four years. The company focuses on developing targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million globally.
09-16 20:05
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
09-02 02:34
Annexon (ANNX) 2026年第二季度业绩电话会议：ARCHER II试验扩大，BLA申请按计划推进
Annexon的2026财年第二季度业绩电话会议涵盖了ARCHER II研究新的第24个月终点、FORWARD研究的初步数据，以及计划于第四季度提交的tanruprubart BLA（生物制品许可申请）。
08-17 08:01
Citizens Upgrades Annexon to Market Perform
Citizens analyst Jonathan Wolleben upgrades Annexon (NASDAQ:ANNX) from Market Underperform to Market Perform.
08-13 21:48
Annexon Biosciences highlights pivotal 2026 clinical progress
Annexon Biosciences ( ($ANNX) ) has provided an announcement. On August 12, 202...
08-12 18:58
Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 17.65 percent increase over losses of $(0.34) per share from the same period last year.
08-12 18:14
Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy
Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the curre...
08-12 18:03
